Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.Journal of Hematology & Oncology|April 21, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Luca Paruzzo, Vrutti Patel, et al.Blood Advances|November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomasElise A Chong, Elicia Penuel, Ellen B Napier, et al.The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.Blood Advances|December 19, 2023
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.The Journal of Infectious Diseases|July 25, 2024
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic LeukemiaElise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, et al.Blood Cancer Journal|March 24, 2026
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective studyMatthew Hamby, Brian L Egleston, Zachary A K Frosch, et al.Pageof 1